355 related articles for article (PubMed ID: 18699977)
1. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.
Nandurkar S
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1165-7. PubMed ID: 18699977
[No Abstract] [Full Text] [Related]
2. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.
Miyamoto M; Haruma K; Takeuchi K; Kuwabara M
J Gastroenterol Hepatol; 2008 May; 23(5):746-51. PubMed ID: 18028348
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
[TBL] [Abstract][Full Text] [Related]
4. Addition of prokinetic therapy to a PPI in reflux diseases.
Hsu YC; Lin HJ
Aliment Pharmacol Ther; 2011 Apr; 33(8):983-4; author reply 984-5. PubMed ID: 21434953
[No Abstract] [Full Text] [Related]
5. New pharmacologic approaches in gastroesophageal reflux disease.
Armstrong D; Sifrim D
Gastroenterol Clin North Am; 2010 Sep; 39(3):393-418. PubMed ID: 20951909
[TBL] [Abstract][Full Text] [Related]
6. [Prokinetics of gastrointestinal system; its newer aspects with regard to motillity stimulants].
Hongo M; Satake M
Nihon Rinsho; 2002 Feb; 60 Suppl 2():382-8. PubMed ID: 11979811
[No Abstract] [Full Text] [Related]
7. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
Miyamoto M; Manabe N; Haruma K
Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
[TBL] [Abstract][Full Text] [Related]
8. New pharmacological agents for the treatment of gastroesophageal reflux disease.
Vakil N
Rev Gastroenterol Disord; 2008; 8(2):117-22. PubMed ID: 18641594
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study.
Miwa H; Inoue K; Ashida K; Kogawa T; Nagahara A; Yoshida S; Tano N; Yamazaki Y; Wada T; Asaoka D; Fujita T; Tanaka J; Shimatani T; Manabe N; Oshima T; Haruma K; Azuma T; Yokoyama T;
Aliment Pharmacol Ther; 2011 Feb; 33(3):323-32. PubMed ID: 21118395
[TBL] [Abstract][Full Text] [Related]
10. Clinical considerations in GERD (gastroesophageal reflux disease) therapy: focus on cisapride.
Snape WJ
Am J Manag Care; 1997 May; 3(5):766-71. PubMed ID: 10184748
[TBL] [Abstract][Full Text] [Related]
11. Prokinetics in the treatment of gastro-oesophageal reflux disease. International symposium. Paris, France, 5 September 1996.
Heading RC; Baldi F; Holloway RH; Janssens J; Jian R; McCallum RW; Richter JE; Scarpignato C; Sontag SJ; Wienbeck M
Eur J Gastroenterol Hepatol; 1998 Jan; 10(1):87-93. PubMed ID: 9512959
[No Abstract] [Full Text] [Related]
12. Pharmacological management of GERD: where does it stand now?
Hershcovici T; Fass R
Trends Pharmacol Sci; 2011 Apr; 32(4):258-64. PubMed ID: 21429600
[TBL] [Abstract][Full Text] [Related]
13. Symptom evaluation in gastroesophageal reflux disease.
Modlin IM; Moss SF
J Clin Gastroenterol; 2008; 42(5):558-63. PubMed ID: 18364584
[TBL] [Abstract][Full Text] [Related]
14. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Friedlander EA; Pallentino J; Miller SK; VanBeuge SS
J Am Acad Nurse Pract; 2010 Dec; 22(12):674-83. PubMed ID: 21129076
[TBL] [Abstract][Full Text] [Related]
15. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.
Ren LH; Chen WX; Qian LJ; Li S; Gu M; Shi RH
World J Gastroenterol; 2014 Mar; 20(9):2412-9. PubMed ID: 24605040
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for gastroesophageal reflux disease.
Boeckxstaens GE
Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease.
Ruigómez A; Hungin AP; Lundborg P; Johansson S; Wallander MA; García Rodríguez LA
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):232-7. PubMed ID: 21258240
[TBL] [Abstract][Full Text] [Related]
18. On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor.
Juul-Hansen P; Rydning A
Aliment Pharmacol Ther; 2009 Jan; 29(2):207-12. PubMed ID: 19006541
[TBL] [Abstract][Full Text] [Related]
19. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study.
Ferrús JA; Zapardiel J; Sobreviela E;
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1269-78. PubMed ID: 19474743
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to short-term proton pump inhibitor treatment in laryngopharyngeal reflux patients.
Siupsinskiene N; Adamonis K; Toohill RJ; Sereika R
J Laryngol Otol; 2008 Nov; 122(11):1206-12. PubMed ID: 18331659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
